Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

山 東 威 高 集 團 醫 用 高 分 子 製 品 股 份 有 限 公 司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

VOLUNTARY ANNOUNCEMENT

POSSIBLE SPIN-OFF AND SEPARATE LISTING OF THE

BUSINESS FOCUSING ON DISPOSABLE MEDICAL DEVICES FOR VASCULAR AND CANCER-RELATED INTERVENTIONAL PROCEDURES

This announcement is made by 山東威高集團醫用高分子製品股份有限公司 Shandong Weigao Group Medical Polymer Company Limited* (the "Company") on a voluntary basis.

The Company is considering a possible spin-off and separate listing of its business in the research and development, manufacturing, and sale and distribution of disposable medical devices for radiology, vascular, cardiology and oncology interventional procedures (the "Spin-offBusiness") on a recognized stock exchange (the "Possible Spin-offand Listing").

In the event that the Company proceeds with the Possible Spin-off and Listing, it will constitute a spin-off of the Spin-off Business by the Company subject to compliance with Practice Note 15 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") and will also be a deemed disposal of an interest in the Spin-off Business by the Company under Rule 14.29 of the Listing Rules.

The Company will make further announcement(s) as and when appropriate in compliance with the requirements of the Listing Rules.

1

As at the date of this announcement, the details of the Possible Spin-off and Listing have not been finalised. Shareholders of the Company and potential investors should note that the Possible Spin-off and Listing is subject to, among others, approvals from the relevant regulatory authorities and market conditions. There is no assurance that the Possible Spinoff and Listing will proceed or as to when it may take place. Shareholders of the Company and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board

Shandong Weigao Group Medical Polymer Company Limited

Zhang Hua Wei

Chairman

Weihai, Shandong, the PRC, 14 September 2020

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (Executive Director)

Mr. Long Jing (Executive Director)

Mr. Wang Yi (Executive Director)

Mr. Gong Jian Bo (Executive Director)

Mrs. Zhou Shu Hua (Non-executive Director)

Mr. Lo Wai Hung (Independent non-executive Director)

Mrs. Fu Ming Zhong (Independent non-executive Director)

Mrs. Wang Jin Xia (Independent non-executive Director)

  • for identification purposes only

2

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Shandong Weigao Group Medical Polymer Co. Ltd. published this content on 15 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2020 04:09:04 UTC